Serotonin transporter-ibogaine complexes illuminate mechanisms of inhibition and transport.
Jonathan A. Coleman, Dongxue Yang, Zhiyu Zhao, Po-Chao Wen, Craig Yoshioka, Emad Tajkhorshid, Eric Gouaux
Nature May 1, 2019 DOI: 10.1038/s41586-019-1135-1 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Structural study using cryo-electron microscopy Peer reviewed |
|---|---|
| Population | In vitro (SERT complexes) |
| Topics | Ibogaine Serotonin |
| Keywords | Sert Brain's serotonin transporter Natural compound Molecular mechanism Protein structure Structural changes Fundamental mechanism Brain chemistry Brain signals Chemical signals Pharmacology Drug action Antidepressant Inhibition |
| Citations | 301 |
| Key points | Cryo-electron microscopy structures of SERT-ibogaine complexes in outward-open, occluded, and inward-open conformations define the structural rearrangements during neurotransmitter transport and provide insight into ibogaine inhibition. |
Abstract
The serotonin transporter (SERT) regulates neurotransmitter homeostasis through the sodium- and chloride-dependent recycling of serotonin into presynaptic neurons1-3. Major depression and anxiety disorders are treated using selective serotonin reuptake inhibitors-small molecules that competitively block substrate binding and thereby prolong neurotransmitter action2,4. The dopamine and noradrenaline transporters, together with SERT, are members of the neurotransmitter sodium symporter (NSS) family. The transport activities of NSSs can be inhibited or modulated by cocaine and amphetamines2,3, and genetic variants of NSSs are associated with several neuropsychiatric disorders including attention deficit hyperactivity disorder, autism and bipolar disorder2,5. Studies of bacterial NSS homologues-including LeuT-have shown how their transmembrane helices (TMs) undergo conformational changes during the transport cycle, exposing a central binding site to either side of the membrane1,6-12. However, the conformational changes associated with transport in NSSs remain unknown. To elucidate structure-based mechanisms for transport in SERT we investigated its complexes with ibogaine, a hallucinogenic natural product with psychoactive and anti-addictive properties13,14. Notably, ibogaine is a non-competitive inhibitor of transport but displays competitive binding towards selective serotonin reuptake inhibitors15,16. Here we report cryo-electron microscopy structures of SERT-ibogaine complexes captured in outward-open, occluded and inward-open conformations. Ibogaine binds to the central binding site, and closure of the extracellular gate largely involves movements of TMs 1b and 6a. Opening of the intracellular gate involves a hinge-like movement of TM1a and the partial unwinding of TM5, which together create a permeation pathway that enables substrate and ion diffusion to the cytoplasm. These structures define the structural rearrangements that occur from the outward-open to inward-open conformations, and provide insight into the mechanism of neurotransmitter transport and ibogaine inhibition.
In the evidence
This study is part of the evidence base for a synthesis in the library. Here is how each one recorded it.
-
State of the evidence: Ibogaine Supports
Cryo-electron microscopy structures of SERT-ibogaine complexes captured outward-open, occluded, and inward-open conformations, defining the structural rearrangements during transport and ibogaine inhibition.
Synthesized
Citations in the library
Cited by 31
- The promises and perils of psychedelic pharmacology for psychiatry. Nature Reviews Drug Discovery June 1, 2022
- Structure-based discovery of conformationally selective inhibitors of the serotonin transporter. Cell May 11, 2023
- Serotonin 2A Receptor (5-HT2AR) Agonists: Psychedelics and Non-Hallucinogenic Analogues as Emerging Antidepressants Chemical Reviews November 30, 2023
- The role of neurotrophic factors in novel, rapid psychiatric treatments. Neuropsychopharmacology 2024
- The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology International Journal of Molecular Sciences January 10, 2023
and 26 more in the library
Cites 5
- Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. Journal of Biological Chemistry October 5, 2007
- The mechanistic basis for noncompetitive ibogaine inhibition of serotonin and dopamine transporters. Journal of Biological Chemistry May 25, 2012
- Identification of a primary metabolite of ibogaine that targets serotonin transporters and elevates serotonin. Life Sciences 1995
- Ibogaine and addiction in the animal model, a systematic review and meta-analysis. Translational Psychiatry May 31, 2016
- Control of serotonin transporter phosphorylation by conformational state. Proceedings of the National Academy of Sciences May 17, 2016